Angle PLC
LSE:AGL

Watchlist Manager
Angle PLC Logo
Angle PLC
LSE:AGL
Watchlist
Price: 9.6 GBX 2.67% Market Closed
Market Cap: 31m GBX
Have any thoughts about
Angle PLC?
Write Note

Angle PLC
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Angle PLC
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Angle PLC
LSE:AGL
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Other Current Assets
$387.3m
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
41%
EKF Diagnostics Holdings PLC
LSE:EKF
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Other Current Assets
$2.7m
CAGR 3-Years
546%
CAGR 5-Years
206%
CAGR 10-Years
N/A
No Stocks Found

Angle PLC
Glance View

Market Cap
31m GBX
Industry
Health Care

ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.

AGL Intrinsic Value
21.81 GBX
Undervaluation 56%
Intrinsic Value
Price

See Also

Back to Top